In prostate cancer, PSMA uptake has been observed to increase over time, and dual-timepoint imaging (0–5 min and 55–60 min post-injection) is under investigation, suggesting the potential to improve diagnostic accuracy [30, 31]. The gene discussed is FOLH1; the disease is prostate carcinoma.